
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

**FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June, 2007

ANGIOTECH PHARMACEUTICALS, INC.
(Registrant's name)

**1618 Station Street,
Vancouver, B.C.
Canada V6A 1B6
(604) 221-7676**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

Form 20-F _____ Form 40-F X

Indicate by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.

Yes _____ No X

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-_____.

THIS REPORT ON FORM 6-K SHALL BE DEEMED TO BE INCORPORATED BY
REFERENCE IN THE COMBINED REGISTRATION STATEMENT ON FORMS F-
10, F-4 AND S-4 AND ANY AMENDMENT THERETO (FILE NO. 333-141155) OF
ANGIOTECH PHARMACEUTICALS, INC. (AND ITS SUBSIDIARIES LISTED
THEREIN UNDER THE HEADING "ADDITIONAL REGISTRANTS") AND TO BE
A PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS FURNISHED,
TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS
SUBSEQUENTLY FILED OR FURNISHED.

EXHIBIT INDEX

Exhibit Number	Description of Document
1.	Report of Voting Results for shareholders' meeting held on June 7, 2007

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes," "may," "will," "estimate," "continue," "anticipates," "intends," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the region in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statement contained herein to reflect future result, events or developments.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ANGIOTECH PHARMACEUTICALS, INC.

Date: June 11, 2007

By: /s/

Name: K. Thomas Bailey

Title: Chief Financial Officer

Exhibit 1

Report of Voting Results

This report is filed pursuant to Section 11.3 of National Instrument 51-102 and relates to the results of voting at the annual general meeting of Angiotech Pharmaceuticals, Inc. held on June 7, 2007.

Description of Matter

Outcome of Vote

Resolution to fix the number of directors at six as proposed.

Resolution passed by the requisite majority. ⁽¹⁾

Resolution to elect directors as proposed.

Each nominee for director was elected. ⁽¹⁾

Resolution to appoint PricewaterhouseCoopers LLP as auditors until the next annual general meeting and that the remuneration of the auditors be determined by the Board of Directors.

Resolution passed by the requisite majority. ⁽¹⁾

(1) These votes were conducted by show of hands.

DATED this 11th day of June, 2007.

ANGIOTECH PHARMACEUTICALS, INC.

/s/ David M. Hall

**David M. Hall, Chief Compliance Officer
and Corporate Secretary**